CRISPR THERAPEUTICS AG Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 195.83K shares, a 186.01% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 130.23K shares, a 225.61% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 134.29K shares, a 119.94% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 483.64K shares, a 199.44% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 726.40K shares, a 19.30% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 900.14K shares, a 21.26% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 742.29K shares, a 39.92% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.24M shares, a 0.77% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 195.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 943.99K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 130.23K shares 10-Q · filed 2026-05-04 | 816.63K shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 134.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | 726.40K shares 10-K · filed 2026-02-12 |
| 2025-09-30 | 483.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 653.16K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 68.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 331.04K shares derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | 40.00K shares 10-Q · filed 2025-05-06 | 307.45K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 61.06K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | 900.14K shares 10-K · filed 2025-02-11 |
| 2024-09-30 | 161.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 994.28K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 44.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 849.67K shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 632.68K shares 10-Q · filed 2024-05-08 | 1.22M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 155.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | 742.29K shares 10-K · filed 2024-02-21 |
| 2023-09-30 | 16.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 769.17K shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 411.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 1.15M shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 159.18K shares 10-Q · filed 2023-05-08 | 1.13M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 182.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | 1.24M shares 10-K · filed 2023-02-21 |
| 2022-09-30 | 401.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 1.33M shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 391.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 1.21M shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 261.28K shares 10-Q · filed 2022-05-09 | 1.16M shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 280.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | 1.25M shares 10-K · filed 2022-02-15 |
| 2021-09-30 | 277.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 1.47M shares derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | 344.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | 1.69M shares derived: sum of 4 quarters · filed 2021-07-29 |
| 2021-03-31 | 342.47K shares 10-Q · filed 2021-04-27 | 1.77M shares derived: sum of 4 quarters · filed 2021-04-27 |
| 2020-12-31 | 506.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | 1.52M shares 10-K · filed 2021-02-16 |
| 2020-09-30 | 500.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | 1.72M shares derived: sum of 4 quarters · filed 2020-10-28 |
| 2020-06-30 | 422.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | 1.43M shares derived: sum of 4 quarters · filed 2020-07-27 |
| 2020-03-31 | 88.47K shares 10-Q · filed 2020-04-28 | 1.12M shares derived: sum of 4 quarters · filed 2020-04-28 |
| 2019-12-31 | 705.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | 1.18M shares 10-K · filed 2020-02-12 |
| 2019-09-30 | 211.36K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | |
| 2019-06-30 | 114.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | |
| 2019-03-31 | 148.74K shares 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |